Mutation in CDC42 Gene Set as a Response Biomarker for Immune Checkpoint Inhibitor Therapy
Cancer Medicine · 2025
DOI: 10.1002/cam4.70556 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Kun Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Biomarkers, Tumor, cdc42 GTP-Binding Protein, Mutation. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Youth Innovation Promotion Association CAS, National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors (ICIs) have achieved great success; however, a subset of patients exhibits no response. Consequently, there is a critical need for reliable predictive biomarkers. Our focus is on CDC42, which stimulates multiple signaling pathways promoting tumor growth. We hypothesize that an impaired function of CDC42 may serve as an indicator of a patient's response to ICI therapy.
Methods
We consider CDC42 and its downstream binding and effector proteins as a gene set, as mutations in these components could lead to defective CDC42 function. To elucidate the biomarker function of mutations within the CDC42 gene set, we curated a comprehensive discovery dataset that included seven ICI treatment cohorts. And we curated two ICI treatment cohorts for validation. We explored the mechanism based on The Cancer Genome Atlas database. We also examined whether combining a CDC42 inhibitor with ICI could enhance ICI's efficacy.
Results
Mutations in the CDC42 gene set were associated with improved overall survival and progression‐free survival. Furthermore, our analysis of immune response landscapes among different statuses of the CDC42 gene set supports its role as a biomarker. Animal experiments also revealed that the combination of the CDC42 inhibitor (ML141) with anti‐PD‐1 blockade can additively reduce tumor growth.
Conclusions
Our study suggests that the CDC42 gene set mutations could potentially serve as a novel biomarker for the clinical response to ICI treatment. This finding also provides insights into the potential of combining ICI and CDC42 inhibitor use for more efficient patient treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
- The First Affiliated Hospital of USTC (Anhui Provincial Hospital), division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
- Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
- School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China.
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China.
ORCID-Profile: Sulin Zhang
Förderung
- Youth Innovation Promotion Association CAS
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Natural Science Foundation of Shanghai
- SIMM-SHUTCM Traditional Chinese Medicine Innovation Joint Research Program
- Key Technologies R&D Program of Guangdong Province
- Youth Innovation Promotion Association of the Chinese Academy of Sciences
Zitieren
APA
Wang, K., Zhang, Y., Su, Z., Wang, B., Zhou, Y., Tong, X., Xie, C., Luo, X., Zhang, S., & Zheng, M. (2025). Mutation in CDC42 Gene Set as a Response Biomarker for Immune Checkpoint Inhibitor Therapy. Cancer Medicine. https://doi.org/10.1002/cam4.70556
Vancouver
Wang K, Zhang Y, Su Z, Wang B, Zhou Y, Tong X, et al. Mutation in CDC42 Gene Set as a Response Biomarker for Immune Checkpoint Inhibitor Therapy. Cancer Medicine. 2025. doi:10.1002/cam4.70556
BibTeX
@article{Wang2025,
author = {Wang, Kun and Zhang, Yingying and Su, Zhaoming and Wang, Bei and Zhou, Yuanyang and Tong, Xiaochu and Xie, Chengying and Luo, Xiaomin and Zhang, Sulin and Zheng, Mingyue},
title = {Mutation in CDC42 Gene Set as a Response Biomarker for Immune Checkpoint Inhibitor Therapy},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.70556}
}
EUVIMED